Hepatitis A seroprevalence and demographics in Turkish children in Ankara

Saç, Rukiye Ünsal; Bostancı, İlknur; Dallar, Yıldız; Cihan, Goksin; Atlı, Özlem

doi:10.1111/j.1442-200x.2008.02671.x

Cited by 8 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this study suggest that in the range of this study (2–19 years) younger individuals were more likely to be seropositive. This is contrary to earlier studies describing hepatitis A epidemiology where age was one of the strongest predictors of anti-HAVseropositivity [16, 22–25]. Indeed, in countries where HAV vaccination is not provided, and in the USA prior to vaccination, seropositivity rates would increase with age because antibodies acquired through natural infection provide lifelong immunity.…”

Section: Discussioncontrasting

confidence: 76%

“…However, the protective effect of family income against seropositivity acquired through natural infection, although not significant, can be seen in non-vaccinated persons. In developing countries where hepatitis A is endemic, the role of poverty in hepatitis A disease transmission is firmly established [22–25]. In the USA, immigration and international travel, as previously discussed, were factors more strongly associated with the spread of communicable diseases like hepatitis A [9–12, 19, 21, 30–32].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Determinants of anti-hepatitis A antibody seroprevalence in 2- to 19-year-olds in the USA using NHANES 2007–2008

2011

View full text Add to dashboard Cite

SUMMARYThe aim of the study was to describe the epidemiology and determinants of anti-hepatitis A seroprevalence in 2- to 19-year-olds in the USA for 2007–2008. This study was conducted in a sample of 2621 individuals aged 2–19 years in the USA using data from National Health and Nutrition Examination Survey (NHANES) 2007–2008. The overall seroprevalence of anti- hepatitis A virus (HAV) in this population was 39% (95% confidence interval 32·6–45·3). HAV seroprevalence was higher in Mexican Americans than other ethnic groups, in younger persons, and in those who reported previous vaccination compared to those who did not. We concluded that anti-hepatitis A seroprevalence rates are increasing in younger individuals in the USA, indicating a shift of seroprevalence over time due to vaccination status. Findings are consistent with a persistent influx of infection through international travel and migration and highlight the need to discern hepatitis A infection from vaccination status when assessing the effectiveness of vaccination using seroprevalence data.

show abstract

Section: Discussioncontrasting

confidence: 76%

Section: Discussionmentioning

confidence: 99%

Determinants of anti-hepatitis A antibody seroprevalence in 2- to 19-year-olds in the USA using NHANES 2007–2008

2011

View full text Add to dashboard Cite

show abstract

“…The seroprevalence rates were reported between 87 and 43% at the same region in the same age groups previously. 6 - 8 Seropositivity of HAV for the age group of 20 to 29 years was about 67 to 91% in these studies; it was 79% in our study. Although, 100% of patients over 40 years have been exposed to virus, this study shows that HAV seropositivity is declining in young population.…”

Section: Discussioncontrasting

confidence: 43%

Seroprevalence of Hepatitis A Virus Antibodies among the Patients with Chronic Hepatitis B in Turkey

Tülek

Özsoy

et al. 2015

Euroasian Journal of Hepato-Gastroenterology

View full text Add to dashboard Cite

BackgroundHepatitis A virus (HAV) can cause significant pathology in patients with chronic hepatitis B virus (HBV), however, HAV can be prevented by vaccination. The aim of this study was to determine the implication of vaccination against HAV vaccine in patients with chronic hepatitis B.Materials and methodsThe seroprevalence of anti-HAV IgG antibodies was investigated in the patients with chronic hepatitis B. Anti-HAV IgG antibodies were detected by commercially available ELISA kit.ResultsA total of 673 patients (354 males, 319 females with age range of 17-78 years) with chronic hepatitis B were included the study. Hepatitis A virus seropositivity rate was 34% in the patients younger than 20 years, 79% in the age group of 20 to 29 years, and 100% after 35 years of age.DiscussionHepatitis A virus vaccination may be recommended for young adult patients with chronic hepatitis B in Turkey.How to cite this articleTulek N, Ozsoy M, Moroglu C, Sonmezer MC, Temocin F, Ertem GT, Erdinc FS. Seroprevalence of Hepatitis A Virus Antibodies among the Patients with Chronic Hepatitis B in Turkey. Euroasian J Hepato-Gastroenterol 2015;5(2):95-97.

show abstract

“…Epidemiologic monitoring and accurate surveillance of vaccinepreventable diseases play an important role in the selection of vaccines for inclusion in the NIP and the vaccination strategies that are followed. Evidence of decreasing HAV seroprevalence in younger age groups for over more than a decade has been reported in Turkey [3][4][5]. People who are highly susceptible -because of decreased seroprevalence -may live together with people among whom the HAV widely circulates.…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity and Safety of an Inactivated Hepatitis A Vaccine Given with Measles-Mumps-Rubella Vaccine to 12-13 Month Old Turkish Children

Yurdakök¹

2012

J Vaccines Vaccin

View full text Add to dashboard Cite

Background: The epidemiology of hepatitis A in Turkey favors routine vaccination of children. This study assessed compatibility of a monovalent hepatitis A vaccine with the measles-mumps-rubella (MMR) combination vaccine used in the national immunization calendar at 12-13 months of age. Methods: Hepatitis A seronegative participants were randomized equally to hepatitis A vaccine followed by MMR vaccine 28 days later (Group A), MMR vaccine followed by hepatitis A vaccine 28 days later (Group B), or one dose each of hepatitis A and MMR vaccines given on Day 0 (Group C). All participants received a hepatitis A booster dose 6 months later. Results: A total of 470 seronegative (anti-hepatitis A concentration ≥20 mIU/mL) participants were randomized: 188 to Group A, 94 to Group B and 188 to Group C. The hepatitis A seroprotection rates (≥20 mIU/mL), 1 month after the first vaccination were 93.6% (Group A) and 92.7% (Group C) by a microparticle enzyme immunoassay (MEIA). Using a more sensitive electrochemiluminescence immunoassay (ECLIA), the corresponding seroprotection rates were 100 and 99.4%. Non-inferiority of seroprotection against hepatitis A was demonstrated for concomitant versus non-concomitant vaccination using ECLIA, but not MEIA. After booster, all participants had anti-hepatitis titers ≥20 mIU/mL and anti-hepatitis geometric mean concentrations of 5,078 mIU/mL (Group A), 3,271 mIU/mL (Group B) and 4,314 mIU/mL (Group C). Following primary vaccination, measles (≥120 mIU/mL) and mumps (≥ 10 AU/mL) seroprotection rates were 96.5% with both separate and concomitant vaccination. The rubella seroprotection (≥ 10 IU/mL) rates were 97.6 and 96.7% following separate and concomitant vaccination, respectively. Reactogenicity increased slightly with concomitant administration; both vaccines were well tolerated. Conclusions: The immune response to the hepatitis A vaccine was not impaired by concomitant administration with MMR vaccine. Non-inferiority of seroprotection was demonstrated with the more sensitive of two assays used to evaluate anti-hepatitis A antibody. and are infected later in life when they are more likely to develop severe hepatitis A disease. A survey of HAV seroprevalence in Turkey demonstrated clear differences among five regions, with seropositivity in children between 5-9 years of age >80% in the southeast and east, and <50% in central and western regions [6]. Hepatitis A is a reportable disease in Turkey. Hepatitis A incidence in the Izmir region in 2003 was estimated at 27.66/100,000 from case and laboratory reports or 53 cases/100,000 by the capture-recapture method [7]. Seroprevalence and surveillance data in Turkey indicate intermediate endemicity, supporting routine childhood hepatitis A vaccination. As with MMR, the first dose of hepatitis A vaccine is generally Journal of Vaccines & Vaccination Journa l o f V a cc ines & V a c c in ation

show abstract

Hepatitis A seroprevalence and demographics in Turkish children in Ankara

Abstract: Hepatitis A is intermediate endemic in Ankara and children must be vaccinated before school age, in addition to health education and improved sanitation.

Cited by 8 publications

References 12 publications

Determinants of anti-hepatitis A antibody seroprevalence in 2- to 19-year-olds in the USA using NHANES 2007–2008

Determinants of anti-hepatitis A antibody seroprevalence in 2- to 19-year-olds in the USA using NHANES 2007–2008

Seroprevalence of Hepatitis A Virus Antibodies among the Patients with Chronic Hepatitis B in Turkey

Immunogenicity and Safety of an Inactivated Hepatitis A Vaccine Given with Measles-Mumps-Rubella Vaccine to 12-13 Month Old Turkish Children

Contact Info

Product

Resources

About